Obinutuzumab Biosimilar - Research Grade

Obinutuzumab Biosimilar - Research Grade

• Background: Obinutuzumab biosimilar is a humanized anti-CD20 monoclonal antibody of the IgG1 subclass. It recognizes a specific epitope of the CD20 molecule found on B cells. The molecular mass of the antibody is approximately 150 kDa. it is produced by mammalian cell (CHO) suspension culture. It was engineered for reduced fucose content as compared to a typical IgG1 produced in CHO cells.
• Specifications: Detects human CD20. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Obinutuzumab/afutuzumab.
• Product Name Alternative: B-lymphocyte surface antigen B1, Bp35, Leukocyte surface antigen Leu-16, Membrane-spanning 4-domains subfamily A member 1, MS4A1, afutuzumab
• UniProt: P11836
• Host: Humanized
• Species Reactivity: Human
• Target: CD20
• Isotype: IgG1
• Purification Method: This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.
• Concentration: 1.0 - 5.0 mg/mL
• Endotoxin: ≤ 1.0 EU/mg as determined by the LAL method
• Purity: >95% by SDS-PAGE and HPLC
• Buffer: ICH3001-100mL ICH3002-100mL ICH3003-100mL
• Shipping Conditions: Blue ice
• Storage Conditions: Stable for at least one week when stored sterile at 2-8°C. For long term storage aseptically aliquot in working volumes without diluting and store at –80°C. Avoid Repeated Freeze Thaw Cycles.
• Formulation: Phosphate buffered saline (PBS) pH 7.2,with no carrier protein, potassium or preservatives added. BSA and Azide free.
• Isotype Control: https://ichor.bio/product/bulk-human-igg1-isotype-control-ib1-ich2254/